This site uses cookies to deliver our services and to show you relevant ads and presentations. By clicking on "Accept", you acknowledge that you have read and understand our Cookie Policy , Privacy Policy , and our Terms of Use.

Download large cell lymphoma PowerPoint Presentation

Login   OR  Register

Iframe embed code :

Presentation url :


Description :

Available large cell lymphoma powerpoint presentation for free download which is uploaded by search an active user in belonging ppt presentation Health & Wellness category.

Tags :

large cell lymphoma

Home / Health & Wellness / Health & Wellness Presentations / large cell lymphoma PowerPoint Presentation

Large cell lymphoma PowerPoint Presentation

Ppt Presentation Embed Code   Zoom Ppt Presentation

About This Presentation

Description : Available large cell lymphoma powerpoint presentation for free download which is uploaded by search ... Read More

Tags : large cell lymphoma

Published on : Feb 24, 2014
Views : 443 | Downloads : 1

Download Now

Share on Social Media


PowerPoint is the world's most popular presentation software; you can create professional Large cell lymphoma powerpoint presentation with this powerful software easly. And give your presentation on Large cell lymphoma in conference, a school lecture, a business proposal or in webinar.

Uploader spend their valuable time to create this Large cell lymphoma powerpoint presentation slides, to share their knowledgable content with the world. This ppt presentation uploaded by onlinesearch in their relavent Health & Wellness category is available for free download and use according to your industries likefinance,marketing,education,health and many more. provides a platform for marketers, presenters and educationists along with being the preferred search engine for professional PowerPoint presentations on the Internet to upload your Large cell lymphoma ppt presentation slides to BUILD YOUR CROWD!!

User Presentation
Related Presentation
Free PowerPoint Templates
Slide 1 - EBV positive DLBCL of the elderly 2013/04/01 住院總醫師 王智慧 報告 感謝 蕭樑材大夫 指導
Slide 2 - Am. J. Hematol. 86:663–667, 2011.
Slide 3 - diffuse large B-cell lymphoma (DLBCL)~ 31% of all non-Hodgkin lymphoma Burkitt , plasmablastic, NK/T-cell, angioimmunoblastic, Hodgkin, hydroa-like T-cell lymphoma and lymphomas associated with HIV infection, post-transplant lymphoproliferations, and after exposure to certain cytotoxic or immunomodulator agents.
Slide 4 - Patients and Methods January 2002-December 2009, all newly diagnosed DLBCL from the medical records CD20,CD10,bcl-6,MUM1/IRF4 (cutoff: 30%) EBER in ≧20% of malignant cells
Slide 5 - EBV-positive DLBCL of the elderly were defined: (1) age ≧ 50 years, (2) no clinical and/or laboratory evidence of immunodeficiency, (3) diffuse large cell morphology with positive expression of CD20, (4) EBV-encoded RNA positivity in the tumor cells.
Slide 6 - -exclusion- Transformed and primary cutaneous variants of DLBCL coinfection by HIV, hepatitis B, hepatitis C, or human T-lymphotrophic virus-1 clinical suspicion of immunodeficiency such as chronic infections, chronic diarrhea, and chronic eczema chronic disease associated with leucopenia or lymphopenia, or low immunoglobulin levels
Slide 7 - ppt slide no 7 content not found
Slide 8 - AWOD: alive without disease, AWD: alive with disease, NR: no response Oyama score includes age≧ 70 years and presence of B symptoms as adverse risk factors three risk groups, low (0 factors), intermediate (1 factor), and high risk (2 factors).
Slide 9 - Multivariate survival analyses were not attempted due to the small number of cases.
Slide 10 - Results A total of 199 new cases of DLBCL were identified, 28 patients met the criteria, incidence rate of 14% . Median age at diagnosis: 75 years (51~95) . 17 men, 11 women (61% and 39%) 1.5:1. Hb <10 g/dL, platelets <150 x 10^9/L, lymphocytes <1.0x 10^9/L in 61%, 21%, and 37% of the patients, respectively. ECOG >1  18 patients (64%), LDH levels elevated in 11 (41%),
Slide 11 - advanced clinical stages (Stage III or IV) in 14 (50%). N=14 (50%) presented exclusively with nodal disease, n=11 (39%) had nodal and extranodal involvement, n=3 (11%) had primary extranodal disease, involving the stomach in all cases.
Slide 12 - extranodal sites of involvement were GI tract (n=6), lung (n=3), oropharynx (n=3), bone marrow (n =2), adrenals (n=1), skin (n=1), bone (n=1). B symptoms in 12 cases (43%) IPI scores >2 in 16 cases (57%). Low, intermediate, high Oyama scores in 5 (18%), 12 (43%), and 11 (39%) patients
Slide 13 - ppt slide no 13 content not found
Slide 14 - Histology diffuse pattern, large cells (68%) Monomorphic with a centroblastic or immunoblastic morphology, frequent mitoses, usually necrosis (32%) polymorphic large neoplastic cells with immunoblastic morphology admixed with variable amounts of small lymphocytes and histiocytes. All cases showed scattered RS- like cells.
Slide 15 - 19 patients (68%) had a non-germinal center (NGC) and 9 (32%) had a germinal center (GC)-like phenotype.
Slide 16 - Blood. 2004;103:275-282
Slide 17 - Blood. 2004;103:275-282
Slide 18 - ppt slide no 18 content not found
Slide 19 - Therapy
Slide 20 - median follow up of 32 months, 18 patients (64%) have died; 83% from lymphoma progression. OS for the entire group was 5 months and 3-year OS was 33%
Slide 21 - Worse OS age ≥70 years (n= 14; P= 0.002), advanced clinical stage (n= 9; P= 0.02), ALC <1.0x10^9/L (n= 4; P= 0.004). ECOG performance status > 1, hemoglobin <10 g/dL , platelets <200x 10^9/L, elevated LDH levels showed a trend
Slide 22 - 64 mos 5 mos
Slide 23 - 64 mos 8 mos
Slide 24 - Discussion age >70, advanced stage and ALC <1.0 3 109/L ~ a worse OS rate, R-CHOP may derive better CR and OS rates than CHOP Asian studies, incidence 5 ~11% in Western populations, incidence < 5%
Slide 25 - Immunosenescence characterized by decreased number and function of T-cells in peripheral blood and lymph nodes, apoptosis dysregulation, and elevation of levels of proinflammatory molecules Park et al. showed that EBER-positive DLBCL patients showed poorer clinical response and worse OS rates than EBER-negative patients
Slide 26 - In a prior study from our group, the presence of EBER in DLBCL patients was also independently associated with a worse prognosis these studies did not include patients treated with rituximab-containing regimens
Slide 27 - Clin Cancer Res 2007;13:5124–5132.
Slide 28 - Materials and Methods Diagnosis. when more than 50% of the proliferating, often neoplastic appearing cells showed both of the expression of one or more pan–B cell antigens (CD20/CD79a) and/or light-chain restriction and positive signal for in situ hybridization using EBV-encoded small nuclear early region (EBER) oligonucleotides on paraffin section for patients more than 40 y/o without predisposing immunodeficiency
Slide 29 - Among 149 cases fulfilling these criteria, 96 cases with available clinical data set were enrolled For the control group, 107 patients aged over 40 years with EBV-negative DLBCL treated consecutively at Aichi Cancer Center between 1993 and 2000.
Slide 30 - ppt slide no 30 content not found
Slide 31 - Sites of extranodal involvement N= 17 (20%), limited to extranodal sites. N= 27 (31%) had only lymphadenopathies without extranodal involvement, N= 43 (49%) had lymphadenopathies with extranodal involvement.
Slide 32 - polymorphic subtype scattered distribution of Hodgkin and Reed-Sternberg - like giant cells CD 20 (+) EBNA2 stain
Slide 33 - Histologic features diffuse and polymorphic proliferation of large lymphoid cells with a varing degree of reactive components such as small lymphocytes, plasma cells, histocytes, and epithelioid cells ,sometimes accompanied by necrosis and an angiocentric pattern. Often featured by a broad range of B-cell maturation, containing morphologic centroblasts, immunoblasts, and Hodgkin and Reed-Sternberg (HRS)–like giant cells with distinct nucleoli
Slide 34 - morphologically divided into two subtypes: large cell lymphoma (LCL): n=34, having notably dominant areas where large lymphoid cells with relatively monomorphic appearance. polymorphic LPD subtypes: n=62, scattered distribution of large cells in the polymorphous composition.
Slide 35 - The histology was frequently varied from area to area, indicating a continuous spectrum no significant difference in any clinical characteristics and immunophenotype between these two groups
Slide 36 - Phenotypic features LMP1 was positive on the large atypical cells in 67 (94%) out of 71 tested cases. EBNA2 was detected in the nuclei of 16 (28%) of 57 tested cases CD30 was stained more common in age-related EBVpositive B-cell LPDs than in EBV-negative DLBCL (75% vs 13%, P < 0.0001).
Slide 37 - CD10 expression (18% vs 38%, P = 0.015)
Slide 38 - Response to treatment and Kaplan-Meier survival estimates chemoregimens containing anthracycline for 62 patients (79%) and without anthracycline for 7 patients (9%)~EBV+ 40 (63%) of 64 evaluable patients with achieved a CR with initial therapy~EBV+ 95 (91%) of 104 evaluable cases with DLBCL achieved a CR (P < 0.0001).
Slide 39 - 57 deaths in 96 cases of age-related EBV-positive B-cell LPDs , 34 deaths in 107 cases of DLBCL. causes of death available for 47 cases for age-related EBV-positive B-cell LPDs and 29 for DLBCL.
Slide 40 - Deaths (PD and complications such as infections) in 38 and 9 cases, in age-related EBV-positive B-cell LPDs, 23 and 6 cases in EBVDLBCL. The observed differences between two disease groups were not significant (P = 0.870). more than 70 y/o- not significant (P = 0.747).
Slide 41 - 24 mos A significant difference was still found even when accounting for age
Slide 42 - H-I/High IPI
Slide 43 - Low/L-I IPI
Slide 44 - ppt slide no 44 content not found
Slide 45 - score of 0 (n = 18), no adverse factors 56.3 mos score of 1 (n = 39), one factor25.2 mos score of 2 (n = 21) , two factors 8.5 mos Oyama score
Slide 46 - ppt slide no 46 content not found
Slide 47 - 56 mos 25 mos 8.5 mos
Slide 48 - Switzerland, Austria, Italy 8/258 (3.1%)
Slide 49 - OS: 5.5 mos (EBNA2+): 103 mos (DLBCL > 50 y/o) EBV-positive DLBCL of the elderly in the Asian population seems to be more frequent at extranodal sites, e.g. up to 80% Median age: 67.5 y/o no correlation between age and prevalence of EBV in any of the studied DLBCL collectives